Cell and Gene Therapy Tools, and Reagents: Global Markets – PRNewswire

NEW YORK, July 27, 2020 /PRNewswire/ -- Report Scope: The scope of this study encompasses an investigation of the markets cell and gene therapy tools such as GMP proteins, media, cell separation and activation reagents, viral and non-viral, cytokine release syndrome monitoring products, GMP antibodies, leukapheresis instrumentation, immunoassays (multiplex and singleplex) and bioreactors.The analyst examines each tool type, determines its current market status, examines its impact on future markets, and presents forecasts of growth over the next five years.

Read the full report: https://www.reportlinker.com/p05938974/?utm_source=PRN

Technological issues, including the latest trends, are discussed. The analyst examined the industry on a worldwide basis, from both application and demand perspectives, in the major regions of the world.

Report Includes: - 77 data tables - An overview of the global market for immunoassay-based cell and gene therapy tools, and reagents within the life sciences industry - Analyses of the global market trends, with data corresponding to market size for 2017-2019, and projections of compound annual growth rates (CAGRs) through 2024 - Information about in vitro diagnostics (IVD), its background and importance of IVD testing - Discussion on prevalence of infectious disease, metabolic disorders and chronic ailments as drivers of immunoassay testing market - Description of recent technologies such as chemiluminescent immunoassays (CLIA), fluorescent immunoassays, multiplex assays and rapid diagnostic technologies - Evaluation of market potential for immunoassay-based cell and gene therapy tools and reagents, current market size and market forecast, and market share analysis of the leading players engaged - Patent review and new developments, R&D efforts, industrial changes with emphasis on recent investments, and current state of the immunoassay technology - Company profiles of the key market participants, including Bio-Rad Laboratories, Cytiva Life Sciences, Luminex Corp., Millipore Sigma, Thermo Fisher Scientific and STEMCELL Technologies

Reasons for Doing this Study: Gene and cell therapy are emerging as important tools to treat human health.Techniques such as CAR-T therapy have emerged as key ways of treating many different types of cancers.

The promise of gene therapy using technologies such as CRISPR is starting to be realized in clinical trials, and markets are scaling up to treat other diseases as well, particularly rare gene- based diseases.As these therapies are coming to the fore, a new market for tools to develop these therapies using standard methodologies is emerging.

This report will cover what those tools are, how they impact the larger life science tools market, and how they will evolve over the next five years.

Read the full report: https://www.reportlinker.com/p05938974/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Contact Clare: [emailprotected] US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker

http://www.reportlinker.com

Continue reading here:
Cell and Gene Therapy Tools, and Reagents: Global Markets - PRNewswire

Global Stem Cell Therapy Market Analysis Highlights the Impact of COVID-19 2020-2024| Increase in Awareness of Stem Cell Therapy to Boost Market…

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the global stem cell therapy market size and it is poised to grow by USD 588.22 million during 2020-2024, progressing at a CAGR of almost 7% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Although the COVID-19 pandemic continues to transform the growth of various industries, the immediate impact of the outbreak is varied. While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities. Technavios in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis. Download a Free Sample Report on COVID-19 Impacts

Frequently Asked Questions:

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Gilead Sciences Inc., Holostem Terapie Avanzate Srl, Lineage Cell Therapeutics Inc., Lonza Group Ltd., Novartis AG, Nuvasive Inc., Organogenesis Inc., Osiris Therapeutics Inc., RTI Surgical Holdings Inc., and Vericel Corp. are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

An increase in awareness of stem cell therapy has been instrumental in driving the growth of the market.

Technavio's custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations.

Stem Cell Therapy Market 2020-2024: Segmentation

Stem Cell Therapy Market is segmented as below:

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR43432

Stem Cell Therapy Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The stem cell therapy market report covers the following areas:

This study identifies the limited number of FDA-approved stem cell therapies as one of the prime reasons driving the stem cell therapy market growth during the next few years.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavios in-depth research has direct and indirect COVID-19 impacted market research reports.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform

Stem Cell Therapy Market 2020-2024: Key Highlights

Table of Contents:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Type

Customer Landscape

Geographic Landscape

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Originally posted here:
Global Stem Cell Therapy Market Analysis Highlights the Impact of COVID-19 2020-2024| Increase in Awareness of Stem Cell Therapy to Boost Market...

Enthera Pharmaceuticals Raises 28 Million in Series A Financing to Advance Restorative Therapy for Type 1 Diabetes and Inflammatory Bowel Disease -…

MILAN, Italy--(BUSINESS WIRE)--Enthera Pharmaceuticals (Enthera), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, today announces the completion of a 28 million Series A financing round.

The Series A was co-led by seed investor Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, and incoming investor AbbVie, with further investment from the JDRF T1D Fund (the venture capital fund of JDRF) and several Italian investors including a group coordinated by Banor SIM, a group coordinated by Banca Profilo through Arepo Fiduciaria and Indaco Venture Partners SGR. The 28 million raised is the largest VC-backed Series A funding round for an Italian biotechnology company to date.

The Series A marks AbbVies first venture investment into an Italian company. Enthera was also the first European investment of the JDRF T1D fund, who previously invested in the Company during its 4 million seed extension funding round in 2018.

The proceeds from the Series A financing will be used to obtain clinical proof-of-concept through a first-in-human study of Ent001, Entheras lead candidate. Ent001 is the only drug in development with the potential to restore the pancreatic beta cell compartment in type 1 diabetes as well as the original intestine structure in inflammatory bowel disease, in order to re-establish organ function. The funds will also be used to further develop Entheras pipeline.

Commenting on the successful Series A financing, Giovanni Amabile, CEO of Enthera, said: Having renowned investors Sofinnova Partners, AbbVie and JDRF T1D Fund choosing to support us on our journey is great validation of our company strategy and scientific method, and gives credit to the innovative science that is currently underway in Italy.

We have a revolutionary approach that offers a new perspective for intractable diseases such as type 1 diabetes and inflammatory bowel disease, and the funds raised will enable us to accelerate our lead program Ent001 to clinical proof-of-concept. Through this and the development of our wider pipeline, we have the opportunity to bring real hope to patients in need and to provide effective and safe treatments.

Graziano Seghezzi, Managing Partner of Sofinnova Partners, who co-seeded the company, stated: Entheras Series A financing is a fantastic milestone enabled by the leadership of Giovanni who, since his arrival in the company, has expanded its activities into novel therapeutic areas. This is also an opportunity for us to applaud BiovelocITAs role in transforming the breakthrough science originating from Paolo Fiorina and his team into a full-fledged enterprise. Enthera is a salient example of what can be achieved when the critical components of a biotech ecosystem are brought together to accelerate innovation in Italy: World-class science, experienced management, and dedicated financial capital.

Margarita Chavez, Managing Director of AbbVie Ventures and new addition to the Enthera Board of Directors, added: AbbVie Ventures investment in Entheras Series A demonstrates our confidence in the team and their unique approach to treating underserved autoimmune disorders. I look forward to working with Giovanni and rest of the team as we drive the Company and its innovation forward.

Enthera was formed in 2016 on the basis of research by scientific founders Prof. Paolo Fiorina and Dr. Francesca DAddio. The Company is the first spin-off of the Italian biotech accelerator BiovelocITA, founded by Sofinnova Partners, Silvano Spinelli and Gabriella Camboni, which provided the initial seed fund. A seed extension was financed in 2018 by Sofinnova Partners, JDRF T1D fund and the other existing investors.

ENDS

Notes to Editors

About Enthera

Enthera Srl is a biotech company developing first-in-class biologics to transform the treatment paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way. The Companys primary target indications are type 1 diabetes (T1D) and inflammatory bowel disease (IBD).

Enthera's pioneering approach capitalizes on the key discovery of the IGFBP3/TMEM219 pathway, which is involved in beta cell and stem cell apoptosis in pancreas and gut, respectively.

The Company is building a pipeline of inhibitory monoclonal antibodies (mAbs) and fusion proteins targeting the pathway via multiple angles. Its lead program Ent001 is the only drug in development with the potential to restore the endogenous pancreatic stem cell compartment in T1D as well as the original intestine structure in IBD, in order to re-establish organ function.

Enthera is a private company headquartered in Milan, Italy and founded in 2016 by Prof Paolo Fiorina and Dr Francesca DAddio at BiovelocITA, an Italian biotech accelerator. The Company is backed by Sofinnova Partners and JDRF T1D fund. Entheras discovery engine and assets are protected by a broad portfolio of patents.

For more information, visit https://www.entherapharmaceuticals.com/

Connect with us on LinkedIn.

About Sofinnova Partners

Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over 2 billion under management.

For more information, please visit: http://www.sofinnovapartners.com

About AbbVie Ventures

AbbVie Ventures is the corporate venture capital group of AbbVie. We are a strategic investor, investing exclusively in novel, potentially transformational science aligned with AbbVie's core R&D interests. We measure success primarily by the extent to which our investments foster innovation with potential to transform the lives of patients that AbbVie serves. AbbVie Ventures enables its portfolio companies with both funding as well as access to AbbVie's internal network of experts across all phases of drug development, from drug discovery through commercialization.

For more information, please visit http://www.abbvie.com/ventures

For more information about AbbVie, please visit us at http://www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

About the JDRF T1D Fund

The JDRF T1D Fund is a venture philanthropy fund accelerating life-changing solutions to cure, prevent and treat type 1 diabetes (T1D) through catalytic equity investments. Through its investments in partnership with private capital, including venture capital, corporations and foundations, the T1D Fund seeks to attract the private investment necessary to advance therapeutics, devices, diagnostics and vaccines into the hands of those living with T1D. The T1D Fund invests in areas strategically aligned with JDRF, the leading global organization funding T1D research, with an exclusive focus on supporting the best commercial opportunities. The T1D Fund reinvests any realized gains into new investments to further its mission.

http://www.t1dfund.org

BiovelocITA

BiovelocITA S.r.l. is the first Italian accelerator dedicated to biotech. It was founded by Silvano Spinelli, Gabriella Camboni and Sofinnova Partners. Thanks to BiovelocITA, entrepreneurs, scientists and investors can work together to accelerate biotech projects with an international scope and reach the proof of concept that precedes the clinical phase. Set up to offer innovative solutions to the medical community and to patients, BiovelocITA supports the creation and development of innovative biotech companies in all therapeutic areas.

For more information, see: http://www.biovelocita.com

See the original post:
Enthera Pharmaceuticals Raises 28 Million in Series A Financing to Advance Restorative Therapy for Type 1 Diabetes and Inflammatory Bowel Disease -...

Stem Cell Assay Market Growth Drive by the Rising Diversity of Applications – BioSpace

TMR Research announces a new report on the global stem cell assay market. The report examines the historical growth trajectory exhibited by the global stem cell assay market and its latest figures, and further provides reliable forecasts for the stem cell assay market based on complete analysis of the markets database. The report also takes a close look at the regional and competitive dynamics of the global stem cell assay market in order to shed light on the dynamics of the global market more clearly. The report is titled Stem Cell Assay Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 2025.

Testing antineoplastic drugs in order to check their potency in cancer treatment has emerged as a major application for the global stem cell assay market. The testing covers impurity, toxicity, and other aspects of the tumors and provides a qualitative and quantitative analysis of various aspects of the tumor. The comprehensive figures provided by stem cell assays has driven the demand from the global stem cell assay market.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=40

The growing diversity of applications of stem cell assays is likely to be a major driver for the global stem cell assay market. Pluripotent stem cells have been used in the treatment of several diseases so far and are likely to remain a key part of the healthcare sector in the coming years due to their intrinsic potential to transform into a wide variety of cells in the human body. This makes them a highly promising research avenue in the treatment of diverse conditions such as Alzheimers, Parkinsons, diabetes, rheumatoid arthritis, and retinal diseases, apart from cancer. The growing prevalence of neurological and neurodegenerative conditions, particularly among the growing geriatric demographic in developed countries, is thus likely to be a major driver for the global stem cell assay market.

For the purpose of the study, the report segments the global stem cell assay market based on various parameters. For instance, in terms of assay type, the market can be segmented into isolation and purification, viability, cell identification, differentiation, proliferation, apoptosis, and function. By kit, the market can be bifurcated into human embryonic stem cell kits and adult stem cell kits. Based on instruments, flow cytometer, cell imaging systems, automated cell counter, and micro electrode arrays could be the key market segments.

In terms of application, the market can be segmented into drug discovery and development, clinical research, and regenerative medicine and therapy. The growth witnessed across the aforementioned application segments will be influenced by the increasing incidence of chronic ailments which will translate into the rising demand for regenerative medicines. Finally, based on end users, research institutes and industry research constitute the key market segments.

Buy this Premium Report @ https://www.tmrresearch.com/checkout?rep_id=40&ltype=S

Steady research and development in the medical sector is likely to remain a key driver for the global stem cell assay market, as the diversity of application of stem cells is purely potential until applied to specific avenues. Growing government support to the medical sector is likely to help the global stem cell assay market in this regard, as significant investment is required to carry out advanced medical research.

Regionally, North America and Europe are likely to remain the leading contributors to the global stem cell assay market due to the presence of a stable healthcare sector in developed countries in the region. The ready incorporation of technological advancements such as stem cell assays in the day to day functioning of the healthcare sector is the key driver for the stem cell assay market in developed countries such as the U.S., Canada, the U.K., Germany, and France.

The report also profiles leading players in the global stem cell assay market in order to shed light on the competitive dynamics of the market. Stem cell assay market leaders examined in the report include Thermo Fisher Scientific Inc., GE Healthcare, STEMCELL Technologies Inc., Bio-Rad Laboratories Inc., Hemogenix Inc., Cell Biolabs Inc., and Promega Corporation.

Get Table of Content of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=40

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

Rohit Bhisey

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Visit Site: https://www.tmrresearch.com/

Follow this link:
Stem Cell Assay Market Growth Drive by the Rising Diversity of Applications - BioSpace

21 Existing Drugs Identified Appear to Block SARS-CoV-2 Replication in The Lab – ScienceAlert

In an industry where getting one drug developed from lab to clinic can cost hundreds of millions of dollars and decades of time, it helps when scientists can be thrifty and make use of substances that already exist.

A global team of researchers has now done just that, by searching through one of the world's largest collections of already developed drugs to discover 21 potential treatments for COVID-19.

We will need considerably more research to determine if any of these drugs can be used to help COVID-19 patients, but it's an excellent first step, bypassing some of the barriers for producing completely new drugs.

"The development of a vaccine is likely to require at least 12-18months, and the typical timeline for approval of a novel antiviral therapeutic can exceed 10years," the team writes in their new paper.

"Thus, repurposing of known drugs could significantly accelerate the deployment of novel therapies for COVID-19."

The researchers took the ReFRAME Drug Repurposing Library - 11,987 compounds which have either received FDA approval or made it to clinical-trials and began testing them against SARS-CoV-2 ina line of cells called Vero, cultured from the kidney of an African green monkey (Chlorocebus sp.).

"We realised early in the COVID-19 pandemic that ReFRAME would be an invaluable resource for screening for drugs to repurpose against the novel coronavirus," says medical chemist and study co-author Arnab Chatterjeefrom Calibr, the drug discovery division of Scripps Research that created ReFRAME.

As was expected, the vast majority of the tests didn't result in much, but the team did find 100 compounds that inhibited viral replication of SARS-CoV-2 in Vero cells.

The team then demonstrated that 21 of those 100 compounds had a dose-response relationship meaning the dose required to be effective wasn't also likely to cause harm to humans. One of these was remdesivir, so that leaves 20 yet to be tested for COVID-19 treatment.

Of those 21 drugs, 13 were found to be effective at concentrations that could be safely used in COVID-19 patients and had previously entered clinical trials.

"This study significantly expands the possible therapeutic options for COVID-19 patients, especially since many of the molecules already have clinical safety data in humans," said virologist Sumit Chandafrom Sanford Burnham PrebysMedical Discovery Institute in California.

"This report provides the scientific community with a larger arsenal of potential weapons that may help bring the ongoing global pandemic to heel."

The 21 drugs are currently being tested further using small animal models or mini lungs that can mimic human tissue. However, the team has already found three that worked in human stem cell-derived lung tissue, and one showed antiviral effects in a lab-based lung culture system.

This is all exciting stuff, but as we've seen in manyexamples so far, caution is needed before rushing into the administration of new drugs, even during a pandemic - not all promising compounds will actually work against COVID-19, even if those drugs have been approved for other ailments in the past. The more treatments we have however, the better.

"While some of these drugs are currently in clinical trials for COVID-19, we believe it's important to pursue additional drug candidates so we have multiple therapeutic options," says Chanda.

The research has been published in Nature.

Read the original post:
21 Existing Drugs Identified Appear to Block SARS-CoV-2 Replication in The Lab - ScienceAlert

Paralyzed man walks after 11 years with the help of Plexus Neuro and Stem Cell Research Centre, Bengaluru – PR Newswire India

Anand met with an unfortunate road accident and suffered spinal cord injury. He was suddenly propelled from the world of the able-bodied into the world of the disabled. He was paralyzed from below the neck and couldn't even wipe his tears, which emphasized his helplessness. Finally, Plexus entered Anand's life as a glimmer of hope and Anand rehabilitation was seen as a triumphant fight where the treating team played an imperative role.

Dr Naeem Sadiq, Consultant Neurologist, Founder & Director of Plexus Neuro and Stem Cell Research Centre said, "In Anand's 11 years struggle, I saw a possibility of recovery and his father entrusted his hopes and desires on Plexus and then his journey towards recovery started. At Plexus, he was subjected to a customized treatment approach, which was planned after carrying out a critical evaluation of his strengths and weaknesses."

He further said, "A group of Rehabilitation professionals focused on every aspect of his recovery starting from his poor posture to the use of his hands and walking."

His treatment comprised of stem cell therapy & comprehensive rehabilitation program which focused on improving his strength, sensation, daily activities and bowel and bladder control. After an arduous excursion of 120 days, Anand was able to use his hands to hold a spoon and eat, write, wear his clothes and hold a walker to walk independently. His trunk became steady and regained its balance, his legs started bearing weight and he even started feeling his bowel and bladder sensations. Dr Sadiq added, "Anand's recovery defied science and at every step challenged his treating team. Anand's unwavering belief in self, motivation and determination became the highlights of his journey in Plexus."

Anand's 11-year long tussle finally ended at Plexus and this end marked the beginning of a new life for him and his family.

About Plexus

At Plexus,we are committed to providing advanced treatment to effectively treat a host of chronic diseases. Our comprehensive services such as stem cell therapy, physiotherapy, occupational therapy, speech & swallowing therapy, cognitive behaviour therapy, customised hand splinting, sensory integration therapy, cognitive rehabilitation therapy to help, treat and rehabilitate patients suffering from neurological and neuropsychiatric disorders. When you choose Plexus, you can expect swift diagnosis, a warm and friendly environment, and thorough treatment all at an affordable price.

Visithttp://www.plexusnc.com/or call+91-8904842087for more details

Media Contact :

Abhishek Saran [emailprotected] +91-9535046900 The PRview

Photo: https://mma.prnewswire.com/media/1217269/Plexus_Dr_Naeem_Sadiq.jpg

SOURCE Plexus

Read more:
Paralyzed man walks after 11 years with the help of Plexus Neuro and Stem Cell Research Centre, Bengaluru - PR Newswire India

Ayahuasca inspires another biotech startup at ATAI; Mylan TB drug gets green light in India – Endpoints News

We have one more startup to add to the list before we call it a day. ATAI Life Sciences, which likes to dabble with psychedelics in developing new therapies, has another mind bender in the works. Theyve kickstarted a new company to delve into formulations of N,N-dimethyltryptamine (DMT) the active ingredient in ayahuasca for new drugs to use in the mental health field. DMT acts as a partial agonist on a variety of 5-HT receptors, they say, which makes it a good candidate for patients not attracted to the potent brew featured on certain South American journeys. These novel products are expected to simplify in-clinic administration and allow greater pharmacokinetic control of the psychedelic experience and its overall duration, said Srinivas Rao, chief scientific officer of ATAI. Patients may even be able to attend psychotherapy sessions later the same day.

Mylan has received the green light from regulators in India for its tuberculosis drug pretomanid. Its only the third treatment for drug-resistant forms of the disease to be approved in more than 40 years, following J&Js bedaquiline and Otsukas delamanid. India accounts for roughly 25% of the worlds tuberculosis cases, and Covid-19 has raised fears that previous efforts to curtail TB will be hampered. The WHO said in May that an additional 1.4 million people could die from TB within the next five years as a direct result of the Covid-19 pandemic.

The Alzheimers Drug Discovery Foundation has sealed several partnerships with Roche, Shionogi, J&Js Janssen and Eisaito launch a biobank sharing program. Part of the Diagnostics Accelerator, the initiative aims to develop better biomarker tests by analyzing blood and cerebral spinal fluid specimens from Alzheimers patients in earlier clinical trials.

The Ohio State University has spun a company out of Zhiwei Hus lab, providing the seed funding to run more preclinical studies and scale up manufacturing for his next-generation tissue factor (TF) immunotherapies targeting triple-negative breast cancer, among others. CincyTech, a local fund in Cincinnati, led the financing for Eikonoklastes Therapeutics, which is run by former Myonexus exec Bruce Halpryn.

Read this article:
Ayahuasca inspires another biotech startup at ATAI; Mylan TB drug gets green light in India - Endpoints News

Duvelisib May Reduce Lung Inflammation in Severe COVID-19 Cases – OncLive

An Emory University-led phase 2 study will evaluate whether the the PI3K-gamma/delta inhibitor duvelisib (Copiktra) is effective at reducing lung inflammation in patients with severe novel coronavirus 2019 (COVID-19), thereby decreasing incidences of mechanical ventilation and death in these patients.1,2

Investigators theorize that the agent will not only work to reduce inflammation and pulmonary edema, but could also potentially decrease duration of viremia and prompt a response from immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies that could in turn respond to SARS-Cov-2 spike proteins.

The increase in proteins can lead to a cytokine storm, resulting in severe pneumonitis and acute respiratory distress syndrome (ARDS), and can be fatal.1 Investigators hope to reduce the incidence rate of death or mechanical ventilation intervention, which is 40%, to 15% with the use of duvelisib.

Duvelisibs use in COVID-19 comes not from its anti-cancer properties, but its activity in the immune system. Particularly, we found that it can enhance the growth and expansion of T-cells that retain anti-cancer activity, principal study investigator Edmund K. Waller, MD, PhD, a professor in the Departments of Medicine, Pathology, and Hematology and Medical Oncology at Emory University School of Medicine, as well as the medical director of the Center for Stem Cell Processing and Apheresis Emory University Hospital, said in an interview with OncLive. Results from clinical trials in patients with lymphoma show that these patients had lower levels of cytokinesthe inflammatory proteins we believe are a part of COVID-19 pathologywhen theyve been treated with duvelisib compared with other anticancer therapies.

In September 2018, the FDA has approved duvelisib for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or relapsed/refractory follicular lymphoma.

Waller added that duvelisib may help T cells grow and potentially fight COVID-19, while simultaneously modulating the inflammation that could lead to fluid accumulation in patients lungs.

In the study, duvelisib will be administered to patients with COVID-19 over the course of 2 weeks, and investigators will evaluate the agents efficacy in not only reducing the need for mechanical ventilation and the risk of death within 30 days of treatment.

Additional end points include the need for high-flow oxygen devices, supplemental oxygen, and hospitalization with or without ongoing medical care. The targeted enrollment is 80 adults whose ages are 18 years and older who have been confirmed to have severe COVID-19 symptoms, such as pneumonia and difficulty breathing. Patients will then be randomized to either duvelisib (n = 40) or placebo (n = 40). Waller said he hopes to determine whether or not the agent will be effective in managing the virus to prevent patients from being admitted to the intensive care unit. Duvelisib, he added, could provide a valuable third line of defense after the infection has been established.

In a preclinical pharmacology setting, duvelisib was shown to be highly potent, with investigators noting a whole blood IC50 of 0.36 nM for delta subunit inhibition and whole blood IC50 of 19.6nM for gamma subunit inhibition. The agent was shown to double T cells in both patients with CLL, as well as healthy volunteers from 40 nM to 0.4 mM over 9 to 14 days.

Should the study results be positive, Waller said that the data warrant a need for a larger, multicenter study to further confirm the findings. Even in the event of a smaller, but still significant reduction by one-third or more of patients, the research could be expanded to include hundreds of patients with severe COVID-19, he said.

This is a challenging time, concluded Waller. There are more [factors about this virus] that we dont know than we do know. We have to be cautious as new data become available [to ensure] that its rigorously looked at in order to change medical practices based on solid clinical data. Our study is small, and I wont say that it will change clinical practice, but hopefully its a step towards finding better ways to treat these patients.

Go here to read the rest:
Duvelisib May Reduce Lung Inflammation in Severe COVID-19 Cases - OncLive

Stem Cell Banking Market 2020 Analysis, Growth by Top Companies, Trends by Types and Application, Forecast to 2025 – Market Research Posts

The global Stem Cell Banking market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 6.9% in the forecast period of 2020 to 2025 and will expected to reach USD 2146.6 million by 2025, from USD 1644.3 million in 2019.

The Stem Cell Banking market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Get Latest Sample for Global Stem Cell Banking Market Report @https://www.arcognizance.com/enquiry-sample/757101

Market segmentation Stem Cell Banking market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Stem Cell Banking market has been segmented into Umbilical Cord Blood Stem Cell, Embryonic Stem Cell, Adult Stem Cell, Other, etc.

By Application, Stem Cell Banking has been segmented into Diseases Therapy, Healthcare, etc.

Regions and Countries Level Analysis Regional analysis is another highly comprehensive part of the research and analysis study of the global Stem Cell Banking market presented in the report. This section sheds light on the sales growth of different regional and country-level Stem Cell Banking markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Stem Cell Banking market. The report offers in-depth assessment of the growth and other aspects of the Stem Cell Banking market in important countries (regions), including United States, Canada, Mexico, Germany, France, United Kingdom, Russia, Italy, China, Japan, Korea, India, Southeast Asia, Australia, Brazil and Saudi Arabia, etc. It also throws light on the progress of key regional Stem Cell Banking markets such as North America, Europe, Asia-Pacific, South America and Middle East & Africa.

Access Complete Global Stem Cell Banking Market Report @https://arcognizance.com/report/global-stem-cell-banking-market-2020-by-company-regions-type-and-application-forecast-to-2025

Competitive Landscape and Stem Cell Banking Market Share Analysis Stem Cell Banking competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Stem Cell Banking sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Stem Cell Banking sales, revenue and market share for each player covered in this report.

The major players covered in Stem Cell Banking are: CCBC, Crioestaminal, Esperite, CBR, LifeCell, ViaCord, Cordlife, Boyalife, Vcanbio, RMS Regrow, Cryo-cell, Americord, PBKM FamiCord, Familycord, Cellsafe Biotech, StemCyte, cells4life, Krio, PacifiCord, Beikebiotech, Cryo Stemcell, Stemade Biotech, etc. Among other players domestic and global, Stem Cell Banking market share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Buy The Report @https://www.arcognizance.com/purchase/757101

Major Point of TOC:

Chapter One: Stem Cell Banking Market Overview

Chapter Two: Company Profiles

Chapter Three: Market Competition, by Players

Chapter Four: Market Size by Regions

Chapter Five: North America Stem Cell Banking Revenue by Countries

Chapter Six: Europe Stem Cell Banking Revenue by Countries

Chapter Seven: Asia-Pacific Stem Cell Banking Revenue by Countries

Chapter Eight: South America Stem Cell Banking Revenue by Countries

Chapter Nine: Middle East & Africa Revenue Stem Cell Banking by Countries

Chapter Ten: Market Size Segment by Type

Chapter Eleven: Global Stem Cell Banking Market Segment by Application

Chapter Twelve: Global Stem Cell Banking Market Size Forecast (2021-2025)

To Check Discount of Stem Cell Banking Market @https://www.arcognizance.com/discount/757101

If you have any special requirements, please let us know and we will offer you the report as you want.

About Us: Analytical Research Cognizance(ARC)is a trusted hub for research reports that critically renders accurate and statistical data for your business growth. Our extensive database of examined market reports places us amongst the best industry report firms. Our professionally equipped team further strengthens ARCs potential. ARC works with the mission of creating a platform where marketers can have access to informative, latest and well researched reports. To achieve this aim our experts tactically scrutinize every report that comes under their eye.

Contact Us:Ranjeet Dengale Director Sales Analytical Research Cognizance +1 (646) 403-4695, +91 90967 44448 [emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

Read the rest here:
Stem Cell Banking Market 2020 Analysis, Growth by Top Companies, Trends by Types and Application, Forecast to 2025 - Market Research Posts

Comprehensive Report on Stem Cell Banking Market 2020 | Trends, Growth Demand, Opportunities & Forecast To 2026 | Cord Blood Registry Systems,…

Stem Cell Banking Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

Stem Cell Banking Market is growing at a High CAGR during the forecast period 2020-2026. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Get the PDF Sample Copy of This Report:

https://www.a2zmarketresearch.com/sample?reportId=139887

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Top Key Players Profiled in This Report:

Cord Blood Registry Systems, Cordlife, Cryo-Cell International, Cryo-Save Ag (A Subsidiary Of Esperite N.V), Lifecell International, Stemcyte, Viacord (A Subsidiary Of Perkinelmer), Global Cord Blood, Smart Cells International, Vita34, Cryoholdco

The key questions answered in this report:

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Stem Cell Banking market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Stem Cell Banking markets trajectory between forecast periods.

Get Up to 20% Discount on this Premium Report @:

https://www.a2zmarketresearch.com/discount?reportId=139887

Reasons for buying this report:

Table of Contents:

Global Stem Cell Banking Market Research Report

Chapter 1 Stem Cell Banking Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Stem Cell Banking Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=139887

Continued here:
Comprehensive Report on Stem Cell Banking Market 2020 | Trends, Growth Demand, Opportunities & Forecast To 2026 | Cord Blood Registry Systems,...